Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,090 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07865546Recruiting
Advanced brain scans for epilepsy surgery planning
This study uses a very powerful MRI scanner to get detailed images of the brain. It aims to help doctors better understand and plan surgery for people with epilepsy that doesn't improve with medication.
Pisa, ItalyAges 6–65 - NCT06166888RecruitingPhase 1
Study of AK131 for advanced solid tumors
This trial tests a new drug called AK131 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and can help slow or shrink the cancer.
Jinan, ShandongAges 18 years+ - NCT06211790RecruitingPhase 2
Targeted first-line treatment for advanced kidney cancer based on protein profile
This trial tests a first-line precision treatment for clear cell kidney cancer that has spread or cannot be removed. It aims to match the treatment to your cancer's protein profile to improve outcomes.
ShanghaiAges 18–75 - NCT05918094RecruitingPhase 3
Testing new chemo plan plus immunotherapy for stomach cancer
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07863258Recruiting
AI matchmaking for advanced liver cancer treatment
This study uses artificial intelligence to look at tumor samples and MRI scans from people with advanced liver cancer to help choose the best treatment. It aims to make treatment more personalized and effective.
AnderlechtAges 18 years+ - NCT07869069Recruiting
Mobile heart health visits for remote communities
This study brings heart health checkups to Indigenous and remote communities using a mobile health unit. It aims to improve heart disease prevention and make healthcare more accessible.
Québec, QuebecAges 35–65 - NCT06243718Recruiting
Surgery for paralyzed diaphragm nerve
This trial looks at how patients feel and recover after surgery to fix the nerve that controls the diaphragm. It aims to learn about people's experiences to improve care for diaphragmatic paralysis.
Red Bank, New JerseyAges 18–70 - NCT04723316Recruiting
Tumor testing to guide targeted cancer treatment
This trial looks at your tumor (and blood) to find helpful targets so doctors can match you to an experimental targeted therapy, if one fits. It may help by using detailed “tumor profiling” to choose treatments more precisely for your cancer.
BelfastAges 16 years+ - NCT07854899Recruiting
Study of advanced retinal degeneration natural history
This study follows people with advanced retinal degeneration (RCD) to learn how the disease progresses over time. It does not test a new treatment, but the information may help design future treatments.
GhentAges 18 years+ - NCT06182657Recruiting
Nasopharyngeal cancer response to induction chemotherapy
This study looks at how well nasopharyngeal cancer (NPC) responds to the first round of chemotherapy before other treatments. It aims to see if the amount of tumor shrinkage can help predict outcomes and guide future care for people with advanced NPC.
Nanchang, JiangxiAges 18 years+ - NCT06247605RecruitingPhase 3
Study of AL8326 for advanced small cell lung cancer
This trial tests a new oral drug called AL8326 for people with advanced small cell lung cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors and help patients live longer.
Changchun, JilinAges 18 years+ - NCT06249256RecruitingEarly Phase 1
Fast CAR T cells for advanced solid tumors
This trial tests a new type of CAR-T cell therapy called Fast CAR T cells for people with advanced solid tumors. It is designed for patients whose tumors have certain markers (mesothelin and PD-L1) and who have not responded to or cannot tolerate standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06248697RecruitingEarly Phase 1
CAR-T cells targeting MSLN with PD-1/CTLA-4 blockers for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05049057RecruitingPhase 2
Testing a nerve-blocking shot for recent mild TBI
This Phase 2 study tests a medication that blocks a pain signal (a CGRP receptor antibody) in people who recently had a mild traumatic brain injury (mTBI) and are also dealing with post-traumatic headache (PTH). The goal is to see if it can reduce symptoms and improve recovery after the injury.
Fort Bragg, North CarolinaAges 18–50 - NCT06044311RecruitingPhase 2
Vactosertib with chemo and radiation for esophageal cancer
This trial tests whether adding a new drug called vactosertib to standard chemotherapy and radiation before surgery can help treat esophageal adenocarcinoma. It aims to see if the combination is safe and effective for patients with stage II or III disease.
Cleveland, OhioAges 18 years+ - NCT07858760Recruiting
Palliative care journey from home to hospital
This study looks at the experiences of patients who come to the palliative care unit at Strasbourg University Hospital from home or through the emergency department. It aims to understand their care path to improve support for others.
StrasbourgAges 18 years+ - NCT06277024Recruiting
Combination therapy for advanced HER2-negative stomach cancer
This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.
Fuzhou, FujianAges 18–75 - NCT07859488Recruiting
Delirium risk after cancer surgery
After surgery for cancer in the belly area, some older adults become confused or have memory problems. This study looks for early signs in the blood that might predict this, so doctors can help prevent it.
Istanbul, IstanbulAges 65 years+ - NCT07869823RecruitingEarly Phase 1
Skin cancer treatment for head and neck
This trial tests a combination of an immunotherapy drug (cemiplimab) and a special kind of radiation for a type of skin cancer called cutaneous squamous cell carcinoma. It is designed for people whose cancer has come back or is hard to treat with standard surgery or radiation.
St Louis, MissouriAges 18 years+ - NCT07870811Recruiting
Wellness program to improve quality of life after organ transplant
This study tests a program of exercise, education, and other non-drug activities to help people who have had an organ transplant feel better and improve their daily lives. It is for people who are at least one year past their transplant and have some quality-of-life concerns.
Palermo, PalermoAges 25–65 - NCT06219980RecruitingPhase 2
Radiation and immunotherapy before surgery for oral cancer
This trial tests combining radiation therapy with immunotherapy and chemotherapy before surgery for advanced oral or throat cancer. The goal is to see if this approach can shrink the tumor and improve treatment outcomes.
Guangzhou, GuangdongAges 18–70 - NCT06306846RecruitingPhase 2
Radiation and immunotherapy before surgery for head and neck cancer
This study tests giving a short course of targeted radiation (SBRT) along with immunotherapy and a targeted drug before surgery for advanced head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–70 - NCT06313463RecruitingPhase 3
Capecitabine and camrelizumab for TNBC after chemotherapy
This trial tests if combining the chemotherapy pill capecitabine with the immunotherapy drug camrelizumab can help people with triple-negative breast cancer (TNBC) who still have tumor tissue after initial treatment. It is for patients whose breast cancer has structures called tumor-associated lymphoid structures (TLS) and who did not achieve a complete response to neoadjuvant therapy.
Guangzhou, GuangdongAges 18–80 - NCT06314373RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,090 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.